Zaki Hosny

No más puestos en curso

75 años

Health Technology

Consumer Services

Perfil

Zaki Hosny formerly worked at Motif BioSciences, Inc., as Chief Executive Officer & Deputy Chairman from 2011 to 2013, Motif Bio Plc, as Independent Non-Executive Director from 2006 to 2019, and Merck & Co., Inc., as Principal from 1998 to 2007.
Mr. Hosny received his graduate degree from the University of Cambridge.

Antiguos cargos conocidos de Zaki Hosny.

Empresas	Cargo	Fin
MOTIF BIO PLC	Director/Miembro de la Junta	15/11/2019
MERCK & CO., INC.	Corporate Officer/Principal	01/01/2007
Motif BioSciences, Inc. Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY.	Presidente	26/06/2013

Ver el detalle de la experiencia de Zaki Hosny.

Formación de Zaki Hosny.

University of Cambridge

Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Zaki Hosny.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
MERCK & CO., INC.	Health Technology

Empresas privadas	2
Motif BioSciences, Inc. Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY.	Health Technology
Motif Bio Plc Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.	Health Technology